Leukemia

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Mon, 26 Dec 2022 14:24:58 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drugs In Development, 2022, provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline landscape.

Acute lymphocytic leukemia (ALL) is the cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. It enters the blood stream and rapidly progress to other parts of the body such as spleen, lymph nodes and liver. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain and breathing problems. Treatment includes chemotherapy, transfusions, transplant and medications.c

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drug...

$2,000.00

T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Wed, 13 Jul 2022 13:33:41 +0000

Summary

T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter stra...

$2,000.00

Chronic Myelomonocytic Leukemia (CMML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Wed, 13 Jul 2022 13:33:41 +0000

Summary

Chronic Myelomonocytic Leukemia (CMML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Chronic Myelomonocytic Leukemia (CMML) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Myelomonocytic Leukemia (CMML), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced fr...

$2,000.00

B-Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Wed, 13 Jul 2022 13:33:41 +0000

Summary

B-Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the B-Cell Leukemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for B-Cell Leukemia, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/universit...

$2,500.00

B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Wed, 13 Jul 2022 13:33:41 +0000

Summary

B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter stra...

$2,500.00

Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

Tue, 12 Jul 2022 15:59:09 +0000

Summary

Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) targeted therapeutics development and features dormant and discontinued projects.
<...

$2,500.00

Mast Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Tue, 12 Jul 2022 14:45:37 +0000

Summary

Mast Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Mast Cell Leukemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Mast Cell Leukemia, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/...

$2,000.00

B-Cell Chronic Lymphocytic Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Fri, 03 Jun 2022 13:17:15 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide B-Cell Chronic Lymphocytic Leukemia - Drugs In Development, 2022, provides an overview of the B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline landscape.

B-Cell Chronic Lymphocytic Leukemia is a type of slow growing leukemia that affects developing B-lymphocytes (also known as B-cells). Symptoms include swollen lymph nodes (glands) in the neck, under the arms or in the groin, pain or discomfort under the ribs on the left side, due to an enlarged spleen, frequent or repeated infections and slow healing, due to a lack of normal white blood cells, excessive sweating at night and unintentional weight loss. Treatment includes chemotherapy and radiation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide B-Cell Chronic Lymphocytic Leukemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology), complete w...

$2,000.00

Chronic lymphocytic leukemia - Pipeline Insight, 2021

Wed, 08 Sep 2021 15:57:35 +0000

DelveInsight’s, “Chronic lymphocytic leukemia – Pipeline Insight, 2021,” report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Chronic lymphocytic leukemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Chronic lymphocytic leukemia Understanding Chronic lymphocytic leukemia: Overview Chronic lymphocytic leukemia (also called CLL) is a cancer of the blood and bone marrow that usually gets worse slowly. CLL is one of the most common types of leukemia in adults. It often occurs during or after middle age; it rarely occurs in children. In the beginning, CLL does not cause any signs or symptoms and may be found during a routine blood test. Later, signs and symptoms may occur. Some of the major symptoms include: Painless swelling of the lymph nodes in the neck, underarm, st...

$2,500.00

Leukemia Treatment Drugs Markets in China

Wed, 12 May 2021 15:00:05 +0000

China's demand for Leukemia Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2010, 2015 and 2020) and long-term forecasts through 2025 and 2030 are presented. Major producers in China are profiled. The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments’ industry bureaus, industry publications, and our in-house databases. Interviews ar...

$4,000.00

Leukemia Treatment Drugs Industry Forecasts - China Focus

Wed, 12 May 2021 15:00:05 +0000

This study focuses on China’s Leukemia Treatment Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is suffering from minimal i...

$1,800.00

Leukemia Treatment Drugs Companies in China

Wed, 12 May 2021 15:00:05 +0000

This study focuses on China’s Leukemia Treatment Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is s...

$1,800.00

Acute lymphocytic leukemia (ALL) - Pipeline Insight, 2020

Thu, 15 Oct 2020 12:43:30 +0000

This “Acute Lymphocytic Leukemia - Pipeline Insight, 2020” report provides comprehensive insights about 250+ companies and 250+ pipeline drugs in Acute Lymphocytic Leukemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Acute Lymphocytic Leukemia Understanding Acute Lymphocytic Leukemia: Overview Acute lymphocytic leukemia (ALL) is also called acute lymphoblastic leukemia. “Acute” means that the leukemia can progress quickly, and if not treated, would probably be fatal within a few months. "Lymphocytic" means it develops from early (immature) forms of lymphocytes, a type of white blood cell. ALL starts in the bone marrow (the soft inner part of certain bones, where new blood cells are made). Most often, the leukemia cells invade the blood fairly quickly. They can also sometimes spread to othe...

$3,500.00

Hairy Cell Leukemia - Pipeline Review, H1 2020

Thu, 07 May 2020 13:13:49 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hairy Cell Leukemia - Pipeline Review, H1 2020, provides an overview of the Hairy Cell Leukemia (Oncology) pipeline landscape.

Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness and weight loss. Risk factors include exposure to radiation, chemicals and saw dust. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hairy Cell Leukemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hairy Cell Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological a...

$2,000.00

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2020

Mon, 24 Feb 2020 15:56:48 +0000

Summary

GlobalData's clinical trial report, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2020" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic proce...

$2,500.00

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2019

Wed, 11 Dec 2019 11:38:48 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2019, provides an overview of the B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline landscape.

B-Cell Chronic Lymphocytic Leukemia is a type of slow growing leukemia that affects developing B-lymphocytes (also known as B-cells). Symptoms include swollen lymph nodes (glands) in the neck, under the arms or in the groin, pain or discomfort under the ribs on the left side, due to an enlarged spleen, frequent or repeated infections and slow healing, due to a lack of normal white blood cells, excessive sweating at night and unintentional weight loss. Treatment includes chemotherapy and radiation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology), complete with ...

$2,000.00

Adult TCell LeukemiaLymphoma Market Insights, Epidemiology and Market Forecast- 2028

Wed, 13 Nov 2019 11:03:24 +0000

DelveInsight's “Adult T-Cell Leukemia-Lymphoma - Market Insights, Epidemiology and Market Forecast – 2028” report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2017-2028. Markets Covered • United States • EU5 (Germany, France, Italy, Spain and the United Kingdom) • Japan Study Period: 2017-2028 Adult T-Cell Leukemia-Lymphoma Understanding and Treatment Algorithm The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Adult T-Cell Leukemia-Lymphoma in the US, Europe, and Japan are also provided in the report. Adult T-Cell Leukemia-Lymphoma Epide...

$6,250.00

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Pipeline Review, H1 2019

Wed, 27 Mar 2019 16:02:56 +0000

Summary

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) pipeline Target constitutes close to 20 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 - Pipeline Review, H1 2019, outlays comprehensive information on the Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Induced myeloid leukemia cell differentiation protein Mcl-1 also known as Bcl-2-like protein 3 or bcl-2-related protein EATS/Mcl1 is a protein encoded by the MCL1 gene. It is involved in the...

$3,500.00

Chronic Lymphocytic Leukemia: Epidemiology Forecast to 2027

Fri, 21 Dec 2018 11:52:10 +0000

Summary

Chronic lymphocytic leukemia (CLL) (International Statistical Classification of Diseases and Related Health Problems, 10th Revision [ICD-10] code = C91.1), also known as chronic lymphoid leukemia, is a type of cancer of the white blood cells (lymphocytes). CLL affects a particular lymphocyte, the B cell, which accumulates mainly in the bone marrow and blood, and normally fights infection.

GlobalData epidemiologists utilized national databases and robust peer-reviewed journal articles to build the CLL diagnosed incident and diagnosed prevalent cases forecast for the 7MM. The disease definition for CLL was consistent with the ICD-10 code C91.1. Whenever available, country-specific sources were utilized. In cases of data scarcity, appropriate proxies were used to fill the data gaps.

The diagnosed incident cases of CLL in the 7MM will increase from 41,974 cases in 2017 to 50,474 cases in 2027, at an Annual Growth Rate (AGR) of 2.03% over the forecast period. For the majority of the forecast period, the US will have the highest number of diagnosed in...

$3,995.00

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H2, 2018

Fri, 07 Dec 2018 15:32:55 +0000

Summary

GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H2, 2018" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic...

$2,500.00

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H2, 2018

Fri, 07 Dec 2018 15:32:55 +0000

Summary

GlobalData's clinical trial report, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H2, 2018" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic proce...

$2,500.00

Acute Promyelocytic Leukemia Global Clinical Trials Review, H2, 2018

Fri, 07 Dec 2018 15:32:55 +0000

Summary

GlobalData's clinical trial report, “Acute Promyelocytic Leukemia Global Clinical Trials Review, H2, 2018" provides an overview of Acute Promyelocytic Leukemia clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Promyelocytic Leukemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective...

$2,500.00

Hairy Cell Leukemia - Pipeline Review, H2 2018

Thu, 29 Nov 2018 13:32:16 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hairy Cell Leukemia - Pipeline Review, H2 2018, provides an overview of the Hairy Cell Leukemia (Oncology) pipeline landscape.

Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness and weight loss. Risk factors include exposure to radiation, chemicals and saw dust. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hairy Cell Leukemia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hairy Cell Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological a...

$2,000.00

T-Cell Leukemia Global Clinical Trials Review, H2, 2018

Wed, 17 Oct 2018 16:06:20 +0000

Summary

GlobalData's clinical trial report, “T-Cell Leukemia Global Clinical Trials Review, H2, 2018" provides an overview of T-Cell Leukemia clinical trials scenario. This report provides top line data relating to the clinical trials on T-Cell Leukemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive...

$2,500.00

Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2017

Fri, 26 Jan 2018 11:42:36 +0000

“Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2017 provides an overview of Chronic Lymphocytic Leukemia (CLL) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Lymphocytic Leukemia (CLL). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. *Note: C...

$2,500.00